Sample Size Estimation -Replicate design- BE limits [Power / Sample Size]

posted by cakhatri – India, 2017-11-30 10:44 (2427 d 04:37 ago) – Posting: # 18024
Views: 16,242

Dear All,

I would like to know

1.What BE limits should be taken into consideration while estimating sample size for replicate design studies for USFDA & EMA.

Should it be 80-125% ? We normally use FARTSSIE

Why the Question

1. For a product with 51% ISCV (from a completed partial replicate study UKMHRA) by using FARTSSIE we arrived at different sample size for EMA

- Sample size estimated = 27 (80% Power, 95-105% T/R, Method C1, BE Limits 69.84 to 143.19%)
- Sample size estimated = 76 (80% Power, 95-105% T/R, No reference Scaled BE Limits-80-125%)

Which sample size should we consider for pivotal study

Regards
Chirag

Complete thread:

UA Flag
Activity
 Admin contact
23,117 posts in 4,859 threads, 1,647 registered users;
29 visitors (0 registered, 29 guests [including 12 identified bots]).
Forum time: 16:22 CEST (Europe/Vienna)

You can’t really say “similar” if it’s the same again you want.
“Similar” means something different.    Anthony Burgess

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5